Head to head
Adaptive Biotechnologies vs Thermo Fisher Scientific
Side-by-side on the measures that matter, with a plain-English read. Full detail: ADPT · TMO
ADPT
Adaptive Biotechnologies
27.93-0.43%
1-year price shape — +71% over the period
Quant Rating C · 96/100
vs
TMO
Thermo Fisher Scientific
669.54-2.79%
1-year price shape — +17% over the period
Quant Rating C · 61/100
1-year performance, rebased to 100
Thermo Fisher Scientific edges it on the scoreable measures. Thermo Fisher Scientific pays the highest dividend yield; Thermo Fisher Scientific earns the most per share.
| ADPT | TMO | |
|---|---|---|
| Snapshot | ||
| Sector | Diagnostics & Research | Diagnostics & Research |
| Last price | 27.93 | 669.54 |
| Change today | -0.43% | -2.79% |
| 1-year return | +71.1% | +17.2% |
| Market cap | $4.52B | $248.08B |
| 52-week range | 12.00 – 32.21 | 434.50 – 727.56 |
| Valuation | ||
| P/E (TTM) | -62.07 | 35.31 |
| P/E percentile, own 5-yr range | 4th | 89th |
| P/B | 25.65 | 4.53 |
| Dividend yield | 0.00% | 0.27% |
| Profitability & growth | ||
| EPS (TTM) | -0.39 | 17.74 |
| Net profit (TTM) | $-63.13M | $6.57B |
| Revenue (TTM) | $298.01M | $47.35B |
| Provider revenue period date | 2026-09-29 | 2026-09-25 |
| Revenue growth (YoY) | -10.7% | +9.1% |
| Gross margin | 74.2% | 41.1% |
| Operating margin | -16.2% | 18.7% |
| Net margin | -23.7% | 14.9% |
| Free cash flow (TTM) | $-8.82M | $7.60B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-25 |
| Ownership & sentiment | ||
| Institutional ownership | 102.6% | 94.1% |
| Insider activity (12mo) | 0 buy / 50 sell | 20 buy / 30 sell |
| Short interest (% of float) | 7.2% | 1.3% |
| Analyst consensus | 88% buy / 12% hold (8) | 88% buy / 12% hold (16) |
| Analyst price target | $33 (+20%) | $778 (+16%) |
| StockVane view | ||
| StockVane Quant Rating | C (96) | C (61) |
| Company | ||
| Employees | 624 | 125,000 |
| Founded | 2009 | 1956 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.